Tue, 16 Sep 2025

September 09, 2025 | News

CEO Christophe Bourdon Highlights LEO Pharma’s Record Profitability and FDA Approval Milestones

LEO Pharma delivered robust financial performance in H1 2025, marked by strong organic growth, improved profitability, and strategic milestones that strengthen its dermatology leadership. Under CEO Christophe Bourdon’s leadership, the company has enhanced its portfolio, improved margins, and positioned itself for sustainable growth. Key Financial Highlights Revenue Growth: Total revenue reached DKK 6,789M, up 6% YoY (7% CER), driven entirely by organic growth. North America: +28% (CER) — strongest contributor Europe: +1% (CER) Rest of World: +4% (CER) Dermatology Portfolio: Up 8% (CER) YoY, fueled by strategic brands Adtralza®/Adbry® and Anzupgo®, which grew 51% (CER) combined. Critical Care Portfolio: Down 3% (CER) due to prior-year discount reversals. Profitability Surge: Adjusted EBITDA: DKK 1,456M (21% margin vs. 9% in H1 2024). Net Profit: DKK 1,977M vs. a loss of DKK 761M in H1 2024. Cash Flow & Debt: Free cash flow improved to DKK 1,469M; net debt reduced to DKK 9,676M from DKK 11,115M at YE 2024. Strategic Milestones FDA Approval of Anzupgo®: First and only topical pan-JAK inhibitor for chronic hand eczema, U.S. launch expected in Q3 2025. SPEVIGO® Partnership: Exclusive global license from Boehringer Ingelheim, positioning SPEVIGO® as LEO’s third strategic brand. Pipeline Advancements: Positive Phase 3 ADHAND trial results for Adtralza®/Adbry® reinforce the dermatology-focused portfolio. Upgraded 2025 Outlook Revenue Growth: 7-9% CER (up from 6-9%). Adjusted EBITDA Margin: 16-18% (previously 15-18%). Excludes potential impact of the SPEVIGO® partnership. Click here to read more 

September 08, 2025 | News

Roche CEO Thomas Schinecker Delivers Strong H1 2025 Results and Confirms Full-Year Outlook

Roche delivered a solid performance in the first half of 2025, showcasing strong revenue growth, higher profitability, key regulatory approvals, and significant pipeline advancements. Under the leadership of CEO Thomas Schinecker, Roche strengthened its pharmaceuticals portfolio, expanded its innovation pipeline, and maintained confidence in its 2025 outlook. Financial Performance Highlights Group Sales: CHF 30.94B, up 7% at CER (4% in CHF), driven by strong demand for innovative medicines. Pharmaceuticals Division: CHF 23.99B, up 10% CER (6% in CHF), led by Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus, contributing CHF 10.6B in combined sales (+CHF 1.7B YoY). Diagnostics Division: CHF 6.96B, stable at CER, despite -3% in CHF due to China’s healthcare pricing reforms. Core Operating Profit: CHF 12.0B, up 11% CER (6% in CHF), reflecting strong sales and effective cost management. Core EPS (Diluted): CHF 11.08, up 12% CER (8% in CHF). IFRS Net Income: CHF 7.83B, up 23% CER (17% in CHF), supported by operational strength and lower impairment charges. Strategic & Regulatory Milestones Key Approvals: U.S. FDA Approval: Susvimo for diabetic retinopathy and VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for targeted lung cancer treatments. EU Approvals: Itovebi for advanced breast cancer and Evrysdi tablets for spinal muscular atrophy. CHMP Recommendation: Expanded Phesgo label for at-home administration, improving patient convenience. Pipeline Progress: Advanced four breakthrough therapies into Phase III trials: NXT007 for haemophilia A Trontinemab for Alzheimer’s disease Prasinezumab for early-stage Parkinson’s disease Zosurabalpin, a novel antibiotic targeting drug-resistant bacteria Innovation Initiatives: Launch of Elecsys PRO-C3 test for improved liver fibrosis assessment. Strategic collaboration with Broad Clinical Labs to accelerate SBX sequencing technology adoption. U.S. Breakthrough Device Designation for the first AI-driven lung cancer companion diagnostic. Geographic Highlights United States: +10% growth, driven by Xolair, Hemlibra, Ocrevus, Vabysmo, and Phesgo uptake. Europe: +5%, supported by Vabysmo, Ocrevus, Polivy, and Phesgo rollouts. Japan: +5%, fueled by Phesgo, Vabysmo, and PiaSky sales. International Markets: +14%, led by strong performance in China (+9%), Latin America (+14%), and emerging markets. Click here to read more

September 05, 2025 | News

AbbVie CEO Robert A. Michael Reports $15.4B Q2 Revenue, Boosts Full-Year EPS Guidance

Under Robert A. Michael’s leadership, AbbVie strengthened its innovation pipeline with multiple regulatory approvals and strategic R&D advancements, including Rinvoq’s new GCA indication and FDA’s accelerated approval for Emrelis. Combined with robust sales from immunology and neuroscience portfolios, AbbVie continues to solidify its market position. AbbVie Inc. reported Q2 2025 net revenues of $15.42 billion, reflecting a 6.6% year-over-year increase on a reported basis and 6.5% on an operational basis. The company delivered an adjusted diluted EPS of $2.97 (up 12.1%), despite a GAAP diluted EPS of $0.52, impacted by $0.42 per share of acquired IPR&D and milestone expenses. The strong quarter was driven by the immunology and neuroscience portfolios, particularly Skyrizi (up 62%), Rinvoq (up 41%), and Vraylar (up 16%), alongside significant gains in Botox Therapeutic and migraine treatments Ubrelvy and Qulipta. Oncology showed modest growth of 2.6%, while aesthetics faced an 8.1% decline. AbbVie also advanced its pipeline with regulatory approvals, including Rinvoq’s new indication for giant cell arteritis, FDA’s accelerated approval of Emrelis for advanced NSCLC, and promising late-stage trial data for Qulipta and Venclexta combinations. Commenting on the results, Robert A. Michael, AbbVie’s Chairman and CEO, said:"AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform. We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data, and strategic investments in external innovation. Entering the second half of the year, we have substantial momentum and are once again raising our full-year outlook." The company raised its FY2025 adjusted EPS guidance to $11.88 – $12.08, reinforcing confidence in sustained growth across its core therapeutic areas. Click here to read more 

July 05, 2023 | News

Korea's SK bioscience inks agreement on influenza research with Doherty Institute in Australia

SK bioscience, a global innovative vaccine and biotech company based in South Korea, has signed a collaboration agreement on influenza research with the Doherty Institute. The Doherty Institute is a leading biomedical research institute located in Australia, home to researchers from the Royal Melbourne Hospital and the University of Melbourne, and to one of five WHO Collaborating Centres for Reference and Research Influenza (WHOCCRRI) in the world. Under this agreement, SK bioscience and the Doherty Institute will work together to support and further research in influenza biology, vaccines, and antivirals. The programme will include testing of anti-influenza compounds to identify new antivirals, capacity building in low- and middle-incomecountries of the region and the development of a new influenza vaccine platform. SK bioscience plans to establish a proactive response system against influenza, advancing influenza vaccine R&D capability to contribute to public health on a global scale.

July 05, 2023 | News

Germany-Saudi Arabian tie up of $30 M for data-driven multiomic testing

Germany-based Centogene, the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF), have announced a strategic collaboration with the formation of a Joint Venture (JV) to increase local and regional access and rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). Under the terms of the collaboration, Centogene will receive a $30 million mandatory convertible loan from Lifera.  Centogene will provide its leading diagnostics and multiomics expertise to the JV, which together with Lifera's strong local presence and resources, will establish widespread access to local state-of-the-art genetic sequencing tailored to regional needs. The JV will build an advanced laboratory and bioinformatics infrastructure – leveraging the Centogene Biodatabank, the world's largest real-world integrated multiomic data repository in rare disease biobanks globally and neurodegenerative diseases, which has more than 70 million and over 35,000 Saudi Arabian patient datasets. The JV will develop capabilities for genetic testing and interpretation working collaboratively with Centogene globally – serving as a vehicle for large national screening and genomics programs. As such, patients in Saudi Arabia and the GCC, a rapidly growing region with over 56 million inhabitants, will have increased access to the world's most advanced and effective diagnostic offerings, which is at the core of Lifera's strategic objectives, contributing to improving national resilience and health outcomes in Saudi Arabia.

July 05, 2023 | News

Waters Corporation and Princeton University announce multi-year research collaboration

Waters Corporation has announced a multi-year research collaboration with Princeton University, in the US, that will enable scientists, faculty, and students to work together to bring their diverse skills and backgrounds to solve complex challenges in biochemistry and materials science. According to Dr Udit Batra, President and CEO, Waters Corporation, "Together our initial work will focus on improving LC-MS workflows and sample preparation to enable our customers to conduct simpler and faster analyses with even greater precision. In turn, this will help biopharma scientists deliver therapeutics that are safe and highly effective for the treatment of disease, such as oncology and autoimmune diseases." "As a leading global institution of research and teaching, Princeton welcomes collaborations with industry to enrich education and accelerate research and innovation for societal benefit," said Craig Arnold, Princeton University Vice Dean for Innovation and the Susan Dod Brown Professor of Mechanical and Aerospace Engineering. Under the new agreement, the Waters-Princeton collaboration will bring together academic and industry researchers to tap into knowledge and expertise from various scientific domains and disciplines to identify and solve problems that matter. One such research project will focus on novel media for purification to help advance drug development and discovery.

May 15, 2023 | News

Australia launches free programme for SMEs in health and medtech sector

Applications are now open for the 10-week Innovate to Grow programme, which provides SMEs with the knowledge and tools to better identify and understand their research and development (R&D) opportunities

May 15, 2023 | News

Roche launches Institute of Human Biology to accelerate breakthroughs in R&D

The IHB is expected to grow to around 250 scientists and bioengineers over the next four years.

May 05, 2023 | News

BTL To Expands North American Sales Team

To accommodate the company\'s expanding operations, BTL is also nearly doubling the size of its US headquarters in Marlborough, MA, and enhancing its internal departments to support the organization\'s growth.

April 28, 2023 | News

India\'s Healthcare Sector Sees Surge in Demand for Skilled Professionals

Jobseekers too are increasingly looking for opportunities in the healthcare segment, with a massive 52% increase in clicks for healthcare roles.

Page 1 of 21

Featured Recruiters